Literature DB >> 19475311

Low hypobaric bupivacaine doses for unilateral spinal anesthesia.

Luiz Eduardo Imbelloni1, Lúcia Beato, M A Gouveia.   

Abstract

BACKGROUND AND OBJECTIVES: The possibility to achieve unilateral spinal anesthesia with 0.15% bupivacaine was studied with the purpose of minimizing hemodynamic changes, limiting the cephalad dispersion of the anesthetic and promoting a faster recovery.
METHODS: Twenty ASA I - II patients undergoing orthopedic surgeries were given spinal 0.15% hypobaric bupivacaine through a 27G Quincke needle. Dural puncture was performed with patients in the lateral position, with the limb to be operated upwards, and 3.3 ml (5 mg) hypobaric bupivacaine were injected at the rate of 1 ml.15 s(-). Sensory and motor block (pinprick and 0 to 3 scale) were compared between operated and contralateral sides.
RESULTS: Motor and sensory block in operated and contralateral sides were significantly different in all evaluated times. Unilateral spinal anesthesia was achieved in 75% of patients. All patients remained hemodynamically stable, and no one developed post-dural puncture headache.
CONCLUSIONS: Hypobaric bupivacaine (5 mg) is able to provide a predominant unilateral block with the patient being kept twenty minutes in the lateral position. Major unilateral spinal anesthesia advantage is hemodynamic stability.

Entities:  

Year:  2003        PMID: 19475311

Source DB:  PubMed          Journal:  Rev Bras Anestesiol        ISSN: 0034-7094            Impact factor:   0.964


  2 in total

Review 1.  Spinal hemianesthesia: Unilateral and posterior.

Authors:  Luiz Eduardo Imbelloni
Journal:  Anesth Essays Res       Date:  2014 Sep-Dec

2.  Determination of the median effective dose (ED50) of bupivacaine and ropivacaine unilateral spinal anesthesia : Prospective, double blinded, randomized dose-response trial.

Authors:  WeiBing Wang; YuanHai Li; AiJiao Sun; HongPing Yu; JingChun Dong; Huang Xu
Journal:  Anaesthesist       Date:  2017-12       Impact factor: 1.041

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.